In the case of HER2-expressing cancers, the most frequent metastatic sites are: bone, liver, and lung for breast cancer [35]: liver, peritoneum, lung, and bone for esophageal and gastric cancers [36,37]; and liver, lung, and peritoneum for ovarian cancer [38]. This evidence concerns the gene ERBB2 and ovarian carcinoma.